Related references
Note: Only part of the references are listed.Brazil announces ‘fantastic’ results for Chinese-made COVID-19 vaccine, but details remain sketchy
Jon Cohen
SCIENCE (2021)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Zhiwei Wu et al.
LANCET INFECTIOUS DISEASES (2021)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Yanjun Zhang et al.
LANCET INFECTIOUS DISEASES (2021)
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Shilong Yang et al.
LANCET INFECTIOUS DISEASES (2021)